Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 2022, 24: v1–v95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020, 70: 299–312.

Article  PubMed  Google Scholar 

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352: 987–996.

Article  CAS  PubMed  Google Scholar 

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10: 459–466.

Article  CAS  PubMed  Google Scholar 

Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol 2018, 20: iv1–iv86.

Article  PubMed  PubMed Central  Google Scholar 

Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol 2018, 4: 1254–1262.

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol 2016, 131: 803–820.

Article  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro-oncology 2021, 23: 1231–1251.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015, 372: 2499–2508.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-oncology 2014, 16: 81–91.

Article  CAS  PubMed  Google Scholar 

Huang Y, Wang Y, Huang Z. A specific peptide vaccine against IDH1(R132H) glioma. Neurosci Bull 2022, 38: 223–225.

Article  PubMed  Google Scholar 

Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013, 19: 764–772.

Article  CAS  PubMed  Google Scholar 

Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321: 1807–1812.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iorgulescu JB, Sun C, Neff C, Cioffi G, Gutierrez C, Kruchko C, et al. Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. Neuro-oncology 2022, 24: 1989–2000.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer 2020, 20: 471–480.

Article  CAS  PubMed  Google Scholar 

Lane DP. p53, guardian of the genome. Nature 1992, 358: 15–16.

Article  CAS  PubMed  Google Scholar 

Liu Y, Tavana O, Gu W. p53 modifications: Exquisite decorations of the powerful guardian. J Mol Cell Biol 2019, 11: 564–577.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 2015, 520: 57–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001, 1: 233–240.

Article  CAS  PubMed  Google Scholar 

Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 2018, 25: 161–168.

Article  CAS  PubMed  Google Scholar 

Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell Rep 2019, 28: 3010.

Article  CAS  PubMed  Google Scholar 

Bykov VJN, Eriksson SE, Bianchi, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer 2018, 18: 89–102.

Article  CAS  PubMed  Google Scholar 

Pilley S, Rodriguez TA, Vousden KH. Mutant p53 in cell-cell interactions. Genes Dev 2021, 35: 433–448.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu XY, Gerges N, Korshunov A, Sabha N, Khuong-Quang DA, Fontebasso AM, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012, 124: 615–625.

Article  CAS  PubMed  Google Scholar 

Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DTW, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009, 11: 341–347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155: 462–477.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003, 100: 8424–8429.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997, 15: 1179–1189.

Article  CAS  PubMed  Google Scholar 

Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: The role of HSP70 and MDM2. PLoS One 2012, 7: e51426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bargonetti J, Prives C. Gain-of-function mutant p53: History and speculation. J Mol Cell Biol 2019, 11: 605–609.

Article  CAS